STAR-TREC
early rectal cancer; tests no drug
Clinician commentary on STAR-TREC in the sources reviewed for this edition leads to one open question: What evidence and service capability are needed to discuss selective organ preservation confidently without overstating long-term safety or dismissing access-dependent alternatives? Its leading findings: (1) the early long-course advantage is not read as proof of equivalent cancer control. (2) short-course criticism reaches treatment and trial-participation decisions, but dissent is setting-specific. (3) selection, response assessment and capacity for surveillance define the opportunity. 8 more findings follow. 160 sources screened, 84 cited; not all HCPs or all public discussion.
- NCT02945566 ↗
- v1.0.0 · edition 1
- updated Oct 31, 2026
- Deep
11 findings, and what sits behind each
01. The early long-course advantage is not read as proof of equivalent cancer control
13 statements · 12 passages · 8 sources · 5 named voices
Counterview: recorded · Limitations recorded: 3. Feeds the Medical Affairs question.
Draws on: Primary endpoint: Phase III Primary Outcome: Organ Preservation, Secondary endpoints, The comparison, Safety and tolerability, Population and setting.
02. Short-course criticism reaches treatment and trial-participation decisions, but dissent is setting-specific
11 statements · 12 passages · 2 sources · 4 named voices
Counterview: recorded · Limitations recorded: 3. Feeds the Medical Affairs question.
Draws on: The comparison.
03. Selection, response assessment and capacity for surveillance define the opportunity
12 statements · 12 passages · 8 sources · 8 named voices
Counterview: recorded · Limitations recorded: 3. Feeds the Medical Affairs question.
Draws on: Population and setting, The comparison, Primary endpoint: Phase III Primary Outcome: Organ Preservation, Secondary endpoints, Safety and tolerability.
04. Avoiding surgery is not a substitute for knowing pelvic function and treatment harms
9 statements · 6 passages · 3 sources · 4 named voices
Counterview: recorded · Limitations recorded: 3. Feeds the Medical Affairs question.
Draws on: Safety and tolerability, Secondary endpoints, Population and setting, The comparison.
05. Mesorectal-only fields are themselves a perceived innovation, with clinical and planning caveats
13 statements · 10 passages · 5 sources · 5 named voices
Counterview: recorded · Limitations recorded: 3. Feeds the Medical Affairs question.
Draws on: Safety and tolerability, Secondary endpoints.
06. Convenience and access sustain interest in shorter treatment, but cost and sequencing are contested
7 statements · 7 passages · 3 sources · 5 named voices
Counterview: recorded · Limitations recorded: 3. Feeds the Medical Affairs question.
Draws on: The comparison.
07. Dose escalation and contact brachytherapy attract strong support, qualified by size, evidence interpretation and access
11 statements · 13 passages · 4 sources · 5 named voices
Counterview: recorded · Limitations recorded: 3. Feeds the Medical Affairs question.
08. Alternative regimens and added immunotherapy remain questions rather than established improvements
11 statements · 11 passages · 6 sources · 8 named voices
Counterview: recorded · Limitations recorded: 3. Feeds the Medical Affairs question.
Draws on: The comparison, Primary endpoint: Phase III Primary Outcome: Organ Preservation, Secondary endpoints.
09. Preoperative schedule evidence is not treated as a complete answer for definitive organ preservation
14 statements · 13 passages · 1 sources · 5 named voices
Counterview: recorded · Limitations recorded: 3. Feeds the Medical Affairs question.
10. Patient-preference design and recruitment earn praise, while enthusiasm may outrun maturity
15 statements · 15 passages · 12 sources · 9 named voices
Counterview: recorded · Limitations recorded: 3. Feeds the Medical Affairs question.
Draws on: Design and conduct, Primary endpoint: Phase II (Feasibility study) Primary Outcome: Recruitment Rate, Primary endpoint: Phase III Primary Outcome: Organ Preservation, The comparison.
11. Patient stories give organ preservation meaning, but public descriptions can overgeneralize
20 statements · 12 passages · 9 sources · 5 named voices
Counterview: recorded · Limitations recorded: 3. Feeds the Medical Affairs question.
Draws on: Population and setting, Primary endpoint: Phase III Primary Outcome: Organ Preservation.
Counts overlap, since one statement can back several findings. They show what the report kept, not how many clinicians agree. The full report includes the interpretations and source links.
Select a finding to see what the full report holds for it: how many verified HCP statements and of what kind, the passages behind them, the sources and voices, and the counterview and limits it records. Select a part of the trial to see which findings draw on it.
- Finding 1 of 11
The early long-course advantage is not read as proof of equivalent cancer control
- statements
- 13
- passages
- 12
- sources
- 8
- named voices
- 5
What the statements areViews 7Questions and uncertainty 2Clinical experience 0Comparisons 2Restated results and context 2How passages are usedSupporting a statement 16Giving context 0Recorded with the finding- Counterview: recorded
- Limitations: 3
- Feeds the Medical Affairs question
- 4 posts and articles
- 3 podcasts and video
- 1 registry
Draws on: Primary endpoint: Phase III Primary Outcome: Organ Preservation, Secondary endpoints, The comparison, Safety and tolerability, Population and setting.
In the full report: the interpretation in full, all 13 statements cited to source and date, and the 8 sources linked where public.
Thicker lines mean more shared statements. A finding without a line goes beyond the registered design. Counts overlap, since one statement can back several findings, and they show what the report kept, not how many clinicians agree.
The full STAR-TREC report gives each finding its interpretation, the attributed views behind it, counterviews, limits and the verified HCP statements, each linked to the original. Get a complete report free to see what you get.
What evidence and service capability are needed to discuss selective organ preservation confidently without overstating long-term safety or dismissing access-dependent alternatives?
Raised by the leading finding. The report shows what clinicians said and the sources behind it; it does not settle the question.
By the numbers
free- 160HCP commentary sources screened
- 84sources cited by verified HCP statements
- 58named in screened sources
- 56voices cited in the report
- 40cited voices matched to verified clinician profiles
Also in the sources: 11 organizational or shared accounts, not counted as people.
- 303verified statements, each linked to its source
- 75of them from speakers with a confirmed clinical role
- 11findings
Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context. No count estimates how many clinicians hold a view. Size (Deep) is set by the 303 verified statements. Statements from sponsors, hosts and organisations are labelled and count apart from identified clinicians. A confirmed clinical role is one verified by the NPI registry or by the person's own institution's staff page; a role a source only states is not counted.
What's inside
free| Section | Items | Access |
|---|---|---|
| Findings with interpretation, counterviews and limits | 11 | Titles free |
| Detailed analysis | 12 sections | Paid |
| Verified statements with short source quotes and links | 303 | Paid |
| Trial aspects mapped | 15 | Free |
| Sources with links | 84 | Counts free |
| Speaker attribution for cited voices | 56 | Paid |
Trial aspects
15 discussed · 0 no commentary · 0 incomplete| Aspect | Statements | Sources |
|---|---|---|
| Primary endpoint: Phase II (Feasibility study) Primary Outcome: Recruitment Rate | 6 | 6 |
| Primary endpoint: Phase III Primary Outcome: Organ Preservation | 43 | 19 |
| Secondary endpoints | 24 | 14 |
| Population and setting | 17 | 13 |
| The comparison | 40 | 25 |
| Safety and tolerability | 21 | 11 |
| Design and conduct | 20 | 14 |
| Patient-reported function and reasons to avoid competing treatments | 15 | 11 |
| Mesorectal-only fields, anal-canal sparing and planning quality | 18 | 7 |
| Dose escalation and brachytherapy as organ-preservation alternatives | 13 | 4 |
| Travel, radiation capacity, economics and sequence-dependent choices | 10 | 5 |
| Insufficient response, systemic treatment and biomarker-guidance questions | 12 | 7 |
| Preoperative versus definitive dose-response and radiobiological explanations | 16 | 1 |
| Guideline expectations, adoption, collaboration and evidence thresholds | 50 | 27 |
| Patient experience, public communication and support implications | 40 | 19 |
An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.
Sources
free| Channel | Screened | Cited | |
|---|---|---|---|
| X threads | 145 | 70 | |
| Bluesky threads | 7 | 1 | |
| X videos | 4 | 4 | |
| YouTube | 2 | 2 | |
| LinkedIn posts | 1 | 1 | |
| Podcasts | 1 | 1 | |
| Primary sources, cited for context, not screened | |||
| Publications | not screened | 4 | |
| Registry | not screened | 1 | |
max 36 / quarter
- Screened window
- May 1, 2016 → Oct 29, 2026
- Cited window
- May 13, 2016 → Oct 23, 2026
- Retrieved
- Oct 31, 2026
The trial
from ClinicalTrials.gov- Title
- STAR-TREC: Can we Save the Rectum by Watchful Waiting or TransAnal Surgery Following (Chemo)Radiotherapy Versus Total Mesorectal Excision for Early REctal Cancer?
- Registry
- NCT02945566
- Study IDs
- RG_15-011 · 2016-000862-49
- Sponsor
- University of Birmingham
- Design
- Phase 2/Phase 3 · Interventional, randomized, parallel
- Status
- Active, not recruiting
- Enrollment
- 380 estimated
- Registered
- 2016-10-26
- Start
- 2017-06-14 actual
- Primary completion
- 2027-08 estimated
- Primary endpoint
- Phase II (Feasibility study) Primary Outcome: Recruitment Rate
- Interventions
- 3 registered
Scope and limits
freeThis report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.
- Discussion that does not name the trial may be missing from this edition.
- Not yet captured in this edition: a question about evidence for low alpha/beta in rectal cancer and its possible implications for radiotherapy fractionation.
- Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
- 94 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.
- The report describes the sources reviewed for this edition, not all HCPs or all public discussion; discussion frequency and source numbers cannot establish clinician consensus.
- A complete text was unavailable for one review of local versus radical surgery. Its conclusions should not be treated as a comprehensive account of every underlying study.
- The directly included results paper concerns radiotherapy planning. Early clinical comparisons are conveyed through attributed commentary and a linked article summary; those sources do not establish mature 30-month clinical outcomes.
- Individual opinions, relayed presentations, institutional communication and patient anecdotes are different kinds of evidence. Reposting does not establish independent endorsement.
- Clinical roles are unstated or unconfirmed for several named authors. Descriptions of credentials, trial participation or leadership remain attributed to their sources, and do not increase the evidentiary weight of a view.
- Several video passages cannot be assigned to a named speaker from the spoken material. Captions, publisher descriptions and a named person elsewhere in the recording do not resolve those passages.
- Endpoint and population labels are inconsistent in some comments, including a speaker's 18% and approximately 25% statements and another speaker's locally advanced description and numerical characterization. They are preserved as statements, not silently corrected.
- Comparisons involving TREC, OPERA, WW2, NEO, TOWARd, RAPIDO and retrospective series retain their own settings and uncertainties. They are not STAR-TREC results or proof that their populations and regimens are interchangeable.
- Post dates and recruitment updates do not establish readout dates, changes of mind, current practice prevalence or confirmed guideline change.
How reports are built and checked: Methods.
Editions and corrections
freeLast checked for new commentary Oct 31, 2026. A new or changed finding gets a new version number; added evidence alone is a smaller update. No corrections.
Cite this report
Erudio Health. STAR-TREC (NCT02945566): HCP commentary report. Edition 1, v1.0.0. Accepted Oct 31, 2026. https://www.erudio.com/reports/star-trec-nct02945566
For your AI agent
Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.
Help me decide whether to buy the Erudio report "STAR-TREC" (NCT02945566), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.
1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "star-trec-02945566". If you cannot make requests, read https://www.erudio.com/reports/star-trec-nct02945566.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email and the product: the current edition, or 3, 6 or 12 months of weekly updates. Call create_order with report "NCT02945566", that product and email, then show me the quote and the checkout_url to pay by card. If you have a payment client for HTTP 402 payments and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id erudio-nct02945566 and sections ["all"], and summarize the findings for me with their sources. The full report is large (about 500 KB): save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.
When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.Or read the record directly: JSON, Markdown or MCP
curl https://www.erudio.com/reports/star-trec-nct02945566.json
curl https://www.erudio.com/reports/star-trec-nct02945566.md
# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "star-trec-02945566" })release a479f9459d32fb125ae569431eba4a61fc2b9834d6b3b3d6ac60e763ee282234